Contact
searchSearch
HMP Global

APP Institute Oncology

Featured

Christa Braun-Inglis, DNP, APRN, FNP-BC, AOCNP
Conference Coverage
Oncology Paired Preceptor Program Supports Nurse Practitioner Transition to Practice in Hawaii
11/27/2024
Christa Braun-Inglis, DNP, APRN, FNP-BC, AOCNP, assesses the effect implementing an academic-community partnership has on doctor of nursing students who are interested in oncology.
Christa Braun-Inglis, DNP, APRN, FNP-BC, AOCNP, assesses the effect implementing an academic-community partnership has on doctor of nursing students who are interested in oncology.
Christa Braun-Inglis, DNP, APRN,...
11/27/2024
APP Institute Oncology
Marlee Bogema, MSN, APRN, FNP-C
Conference Coverage
Outpatient Bispecific Program Demonstrates Safety and Tolerability in the Community Setting
11/21/2024
Marlee Bogema, MSN, APRN, FNP-C, discusses a protocol developed by a community oncology practice which demonstrated that outpatient administration of bispecific antibodies is both safe and well-tolerated and reduces the number of required...
Marlee Bogema, MSN, APRN, FNP-C, discusses a protocol developed by a community oncology practice which demonstrated that outpatient administration of bispecific antibodies is both safe and well-tolerated and reduces the number of required...
Marlee Bogema, MSN, APRN, FNP-C,...
11/21/2024
APP Institute Oncology
Alrlene Siefker-Radke
Conference Coverage
Beyond Platinum: Current Treatment Approaches for Advanced Bladder Cancer
11/15/2024
Arlene Siefker-Radtke, MD, provides an overview on the current treatment landscape for patients with advanced bladder cancer.
Arlene Siefker-Radtke, MD, provides an overview on the current treatment landscape for patients with advanced bladder cancer.
Arlene Siefker-Radtke, MD,...
11/15/2024
APP Institute Oncology
Caroline Schinke, MD
Oncology Advances
Evaluating Long-Term Efficacy and Safety Results from MonumenTAL-1 on Talquetamab Treatment for Patients With Multiple Myeloma
08/09/2024
Caroline Schinke, MD, Myeloma Center at the University of Arkansas, speaks about the long-term efficacy and safety results from the MonumenTAL-1 trials on talquetamab treatment among patients with MM.
Caroline Schinke, MD, Myeloma Center at the University of Arkansas, speaks about the long-term efficacy and safety results from the MonumenTAL-1 trials on talquetamab treatment among patients with MM.
Caroline Schinke, MD, Myeloma...
08/09/2024
APP Institute Oncology
Samantha Shenoy
Videos
Management Considerations for Oral Toxicities Associated With Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
05/09/2024
Samantha Shenoy, NP, discusses considerations for nurses and advanced practitioners managing patients with relapsed/refractory multiple myeloma experiencing oral toxicities after treatment with talquetamab.
Samantha Shenoy, NP, discusses considerations for nurses and advanced practitioners managing patients with relapsed/refractory multiple myeloma experiencing oral toxicities after treatment with talquetamab.
Samantha Shenoy, NP, discusses...
05/09/2024
APP Institute Oncology
Sarah Smith, Virginia Cancer Specialists
Videos
Post-Progression and Safety Outcomes With First-Line Amivantamab Plus Lazertinib vs Osimertinib for Advanced NSCLC: Best Management Practices
05/08/2024
Sarah Smith, BD, CNMT, discusses findings from the phase 3 MARIPOSA study exploring post-progression and safety outcomes with first-line amivantamab plus lazertinib vs osimertinib for advanced NSCLC and offers guidance for best management...
Sarah Smith, BD, CNMT, discusses findings from the phase 3 MARIPOSA study exploring post-progression and safety outcomes with first-line amivantamab plus lazertinib vs osimertinib for advanced NSCLC and offers guidance for best management...
Sarah Smith, BD, CNMT, discusses...
05/08/2024
APP Institute Oncology
EZH2
Rapid Refresh
Understanding the Role of EZH2 in Cancer Pathogenesis
02/28/2024
This animation explains the role of EZH2 in the regulation of cell growth and the effects of EZH2 overexpression.
This animation explains the role of EZH2 in the regulation of cell growth and the effects of EZH2 overexpression.
This animation explains the role...
02/28/2024
APP Institute Oncology
Beth Finley-Oliver and Rachid Baz, Moffitt Cancer Center
Clinical Pearls
Individualizing Care for Multiple Myeloma: Navigating Treatment Options and Addressing Patient Needs
11/27/2023
Elizabeth Finley-Oliver, MSN, ARNP, AGNP-BC, and Rachid Baz, MD, discuss the treatment landscape for patients with multiple myeloma and how clinicians can individualize care while addressing patient needs.
Elizabeth Finley-Oliver, MSN, ARNP, AGNP-BC, and Rachid Baz, MD, discuss the treatment landscape for patients with multiple myeloma and how clinicians can individualize care while addressing patient needs.
Elizabeth Finley-Oliver, MSN,...
11/27/2023
APP Institute Oncology
EGFR
Rapid Refresh
Understanding the Role of EGFR in Cancer Pathogenesis
11/23/2023
This animation explains the role of EGFR in the regulation of cell growth and the effects of the overexpression of EGFR.
This animation explains the role of EGFR in the regulation of cell growth and the effects of the overexpression of EGFR.
This animation explains the role...
11/23/2023
APP Institute Oncology
Lorinda Coombs
APP Perspectives
Myeloma Care: Patient and Advanced Practice Provider Perspectives
11/17/2023
Lorinda Coombs, PhD, CNS, FNP-BC, AOCNP, discusses results from a survey that inform patients and advanced practice provider perspectives on myeloma care.
Lorinda Coombs, PhD, CNS, FNP-BC, AOCNP, discusses results from a survey that inform patients and advanced practice provider perspectives on myeloma care.
Lorinda Coombs, PhD, CNS,...
11/17/2023
APP Institute Oncology
Oncology Advances: Adverse Event Management Strategies for Patients With MM Receiving Talquetamab
A recent study by Donna Catamero, Mount Sinai School of Medicine, New York, New York, et al, provides guidance on practical management of patients with relapsed/refractory MM receiving ta...

Rapid Refresh

BCMA
Rapid Refresh
Understanding the Role of BCMA in Cancer Pathogenesis
07/23/2024
This animation explains the role of BCMA in the life cycle of plasma cells and the effects of overexpression of BCMA on the abnormal survival of these cells.
This animation explains the role of BCMA in the life cycle of plasma cells and the effects of overexpression of BCMA on the abnormal survival of these cells.
This animation explains the role...
07/23/2024
APP Institute Oncology
BCL2
Rapid Refresh
Understanding the Role of BCL2 in Cancer Pathogenesis
07/23/2024
This animation discusses the role of BCL2 in normal cell function and explains the effects of disruptions in the BCL2 gene on cell signaling.
This animation discusses the role of BCL2 in normal cell function and explains the effects of disruptions in the BCL2 gene on cell signaling.
This animation discusses the...
07/23/2024
APP Institute Oncology
ALK
Rapid Refresh
Understanding the Role of ALK in Cancer Pathogenesis
07/23/2024
This animation explains the role of the ALK oncogene in normal cellular functioning and the effect of an abnormal translocation event where ALK fuses to another gene.
This animation explains the role of the ALK oncogene in normal cellular functioning and the effect of an abnormal translocation event where ALK fuses to another gene.
This animation explains the role...
07/23/2024
APP Institute Oncology
20S Proteasome
Rapid Refresh
Understanding the Role of 20S Proteasome in Cancer Pathogenesis
07/23/2024
This animation explains the role of the 20S proteasome in regulating the cellular life cycle and the effects of disruptions in the ubiquitin proteasome system.
This animation explains the role of the 20S proteasome in regulating the cellular life cycle and the effects of disruptions in the ubiquitin proteasome system.
This animation explains the role...
07/23/2024
APP Institute Oncology
CEACAM5
Rapid Refresh
Understanding the Role of CEACAM5 in Cancer Pathogenesis
07/08/2024
This animation explains the role of the CEACAM5 glycoprotein in the inhibition of cell differentiation and apoptosis, which can promote tumor growth and metastasis.
This animation explains the role of the CEACAM5 glycoprotein in the inhibition of cell differentiation and apoptosis, which can promote tumor growth and metastasis.
This animation explains the role...
07/08/2024
APP Institute Oncology
EZH2
Rapid Refresh
Understanding the Role of EZH2 in Cancer Pathogenesis
02/28/2024
This animation explains the role of EZH2 in the regulation of cell growth and the effects of EZH2 overexpression.
This animation explains the role of EZH2 in the regulation of cell growth and the effects of EZH2 overexpression.
This animation explains the role...
02/28/2024
APP Institute Oncology
EGFR
Rapid Refresh
Understanding the Role of EGFR in Cancer Pathogenesis
11/23/2023
This animation explains the role of EGFR in the regulation of cell growth and the effects of the overexpression of EGFR.
This animation explains the role of EGFR in the regulation of cell growth and the effects of the overexpression of EGFR.
This animation explains the role...
11/23/2023
APP Institute Oncology
CD19
Rapid Refresh
Understanding the Role of CD19 in Cancer Pathogenesis
11/09/2023
This animation explains the role of the CD19 antigen in the primary signaling complex on the surface of B-cells and the effect of overexpression of this antigen.
This animation explains the role of the CD19 antigen in the primary signaling complex on the surface of B-cells and the effect of overexpression of this antigen.
This animation explains the role...
11/09/2023
APP Institute Oncology
BTK
Rapid Refresh
Understanding the Role of BTK in Cancer Pathogenesis
11/09/2023
This animation explains the role of Bruton's tyrosine kinase (BTK) in B-cell development and maturation and the effects of aberrant expression of this oncogene.
This animation explains the role of Bruton's tyrosine kinase (BTK) in B-cell development and maturation and the effects of aberrant expression of this oncogene.
This animation explains the role...
11/09/2023
APP Institute Oncology
HER2
Rapid Refresh
Understanding the Role of HER2 in Cancer Pathogenesis
11/08/2023
This animation explains the role of HER2 in the regulation of cell growth and the negative effects of HER2 overexpression.
This animation explains the role of HER2 in the regulation of cell growth and the negative effects of HER2 overexpression.
This animation explains the role...
11/08/2023
APP Institute Oncology

APP Perspectives

Lorinda Coombs
APP Perspectives
Myeloma Care: Patient and Advanced Practice Provider Perspectives
11/17/2023
Lorinda Coombs, PhD, CNS, FNP-BC, AOCNP, discusses results from a survey that inform patients and advanced practice provider perspectives on myeloma care.
Lorinda Coombs, PhD, CNS, FNP-BC, AOCNP, discusses results from a survey that inform patients and advanced practice provider perspectives on myeloma care.
Lorinda Coombs, PhD, CNS,...
11/17/2023
APP Institute Oncology

Meeting Coverage

Christa Braun-Inglis, DNP, APRN, FNP-BC, AOCNP
Conference Coverage
Oncology Paired Preceptor Program Supports Nurse Practitioner Transition to Practice in Hawaii
11/27/2024
Christa Braun-Inglis, DNP, APRN, FNP-BC, AOCNP, assesses the effect implementing an academic-community partnership has on doctor of nursing students who are interested in oncology.
Christa Braun-Inglis, DNP, APRN, FNP-BC, AOCNP, assesses the effect implementing an academic-community partnership has on doctor of nursing students who are interested in oncology.
Christa Braun-Inglis, DNP, APRN,...
11/27/2024
APP Institute Oncology
Conference Coverage
Advanced Practice Providers Play Pivotal Role in Delivering Cancer Screening Services and Follow-Up Care to Vulnerable Populations
11/21/2024
Advanced practice providers play a unique role in delivering cancer screening services and follow-up care to vulnerable populations, emphasizing the importance of their expertise, accessibility, and patient-centered approach to improving...
Advanced practice providers play a unique role in delivering cancer screening services and follow-up care to vulnerable populations, emphasizing the importance of their expertise, accessibility, and patient-centered approach to improving...
Advanced practice providers play...
11/21/2024
APP Institute Oncology
Dylana Smith, MS, AGPCNP-BC, HNP
Conference Coverage
Boosting Advanced Practice Provider Engagement at Memorial Sloan Kettering Cancer Center
11/21/2024
Dylana Smith, MS, AGPCNP-BC, HNP, discusses an initiative to boost APP engagement at Memorial Sloan Kettering Cancer Center and the growth of the program since its inception.
Dylana Smith, MS, AGPCNP-BC, HNP, discusses an initiative to boost APP engagement at Memorial Sloan Kettering Cancer Center and the growth of the program since its inception.
Dylana Smith, MS, AGPCNP-BC,...
11/21/2024
APP Institute Oncology
Marlee Bogema, MSN, APRN, FNP-C
Conference Coverage
Outpatient Bispecific Program Demonstrates Safety and Tolerability in the Community Setting
11/21/2024
Marlee Bogema, MSN, APRN, FNP-C, discusses a protocol developed by a community oncology practice which demonstrated that outpatient administration of bispecific antibodies is both safe and well-tolerated and reduces the number of required...
Marlee Bogema, MSN, APRN, FNP-C, discusses a protocol developed by a community oncology practice which demonstrated that outpatient administration of bispecific antibodies is both safe and well-tolerated and reduces the number of required...
Marlee Bogema, MSN, APRN, FNP-C,...
11/21/2024
APP Institute Oncology
Conference Coverage
Amivantamab Plus Chemotherapy Prolongs Survival, Post-Progression Outcomes for Patients With Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
11/20/2024
According to second interim analysis results from the MARIPOSA-2 trial, amivantamab plus chemotherapy improved survival and post-progression outcomes compared to chemotherapy alone among patients with EGFR-mutated advanced non-small cell lung...
According to second interim analysis results from the MARIPOSA-2 trial, amivantamab plus chemotherapy improved survival and post-progression outcomes compared to chemotherapy alone among patients with EGFR-mutated advanced non-small cell lung...
According to second interim...
11/20/2024
APP Institute Oncology
Conference Coverage
The Enduring Benefit of Abemaciclib Plus Endocrine Therapy for Patients With HR-Positive, HER2-Negative High-Risk, Early Breast Cancer
11/20/2024
According to the preplanned overall survival interim analysis from the phase 3 monarchE trial, abemaciclib plus endocrine therapy continues to show benefit for patients with HR-positive, HER2-negative high-risk early breast cancer.
According to the preplanned overall survival interim analysis from the phase 3 monarchE trial, abemaciclib plus endocrine therapy continues to show benefit for patients with HR-positive, HER2-negative high-risk early breast cancer.
According to the preplanned...
11/20/2024
APP Institute Oncology
Conference Coverage
Implementation of an IV Push Policy for Antibiotic Administration Within An Oncology Urgent Care Clinic
11/18/2024
Introduction of an IV push policy at an oncology urgent care clinic, led by an advanced practice provider, resulted in increased timely administration of antibiotics prior to hospitalization and a decrease in room dwell time.
Introduction of an IV push policy at an oncology urgent care clinic, led by an advanced practice provider, resulted in increased timely administration of antibiotics prior to hospitalization and a decrease in room dwell time.
Introduction of an IV push...
11/18/2024
APP Institute Oncology
Conference Coverage
Workload Index Proves Valuable in Optimizing Oncology Advanced Practitioner Resourcing
11/18/2024
Findings demonstrate the success of the workload index in supporting daily and longitudinal staffing needs as well as for operational and strategic planning and has improved advanced practitioner morale by demonstrating productivity not...
Findings demonstrate the success of the workload index in supporting daily and longitudinal staffing needs as well as for operational and strategic planning and has improved advanced practitioner morale by demonstrating productivity not...
Findings demonstrate the success...
11/18/2024
APP Institute Oncology
Alrlene Siefker-Radke
Conference Coverage
Beyond Platinum: Current Treatment Approaches for Advanced Bladder Cancer
11/15/2024
Arlene Siefker-Radtke, MD, provides an overview on the current treatment landscape for patients with advanced bladder cancer.
Arlene Siefker-Radtke, MD, provides an overview on the current treatment landscape for patients with advanced bladder cancer.
Arlene Siefker-Radtke, MD,...
11/15/2024
APP Institute Oncology
Conference Coverage
Weekend Infusion Model Reduces Emergency Department Visits and Length of Stay for Oncology Patients
11/14/2024
The expansion of infusion services to a weekend-inclusive model led to less emergency department visits, saved inpatient days, and reduced hospital length of stay for oncology patients, according to data presented at the 2024 JADPRO meeting.
The expansion of infusion services to a weekend-inclusive model led to less emergency department visits, saved inpatient days, and reduced hospital length of stay for oncology patients, according to data presented at the 2024 JADPRO meeting.
The expansion of infusion...
11/14/2024
APP Institute Oncology

Visit Our Other APP Institutes

APP Institute Oncology

 

The Advanced Practice Provider (APP) Institute is a new offering from the Oncology Learning Network that provides microburst education to oncology advanced practitioners. The platform offers year-round digital non-accredited learning modules through animated short videos, multimedia interviews with key opinion leaders, interactive content to test your knowledge, and more!

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use